HAYWARD, Calif., March 5, 2012 /PRNewswire/ -- Anthera
Pharmaceuticals, Inc. (Nasdaq:
ANTH), a biopharmaceutical company developing drugs to treat
serious diseases including cardiovascular and autoimmune disorders,
today announced that it has appointed Dr. Bogdan Dziurzynski to its
board of directors.

"Bogdan's extensive global regulatory expertise and broad
industry experience will offer us a great perspective as we
continue to navigate the evolving FDA regulatory landscape," said
Dr. Christopher S. Henney, Chairman of Anthera Pharmaceuticals.
"His strategic guidance and insight will be invaluable as we
continue to advance our late-stage clinical trials."

Dr. Dziurzynski has a rich history of experience. He
currently serves as a strategic regulatory management consultant to
the biotechnology industry and serves on the Board of Directors of
Dendreon Corporation and the Biologics Consulting Group, Inc. Dr.
Dziurzynski is a fellow and past chairman of the board and a past
president of the Regulatory Affairs Professional Society. He also
serves as an advisory board member of Integrated Biotherapeutics,
Inc. From 1994 to 2001, Dr. Dziurzynski was the Senior Vice
President of Regulatory Affairs and Quality Assurance for
MedImmune, Inc., a biotechnology company. From 1988 to 1994, Dr.
Dziurzynski was Vice President of Regulatory Affairs and Quality
Assurance for Immunex Corporation, a biotechnology company. He has
a B.A. in Psychology from Rutgers University, an M.B.A. from
Seattle University and a Doctorate in Public Administration from
the University of Southern California.

"I am pleased to join the Anthera board at such an important
time for the company. I look forward to working with such an
accomplished group," commented Dr. Dziurzynski on his
appointment.